stockrow
Saturday 7 November 2026
Export ABPO’s income statement to Excel — free account
Abpro Holdings Inc.
ABPO Healthcare Biotechnology
Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023.
- EPS
- +89.3%
- Free cash flow
- −0.48%
Quarter to June 2026, against a year earlier
0.58
0.02
+3.57%
Follow ABPO
Alert me
Abpro Holdings Inc. (ABPO) P/E ratio
As of 6 November 2026, Abpro Holdings Inc. (ABPO) trades at a P/E ratio of 0.5×. Over the past ten years it has ranged from 0.0× (June 2026) to 87.6× (March 2023); the current reading is higher than 83% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 87.6×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| OGEN Oragenics, Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.2× |
| ABPO Abpro Holdings Inc. | 0.5× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)